Mike Wach MD
@MikeWach_MD
Followers
792
Following
9K
Media
25
Statuses
236
Surgical Oncologist @MoffittNews, Alumni of @PittSurgOnc, Research @NCI_SurgOncFel. Buffalo Bills fan, Runner, and Hiker.
Tampa, FL
Joined November 2020
First day in the new office ✅ First day in the new OR ✅ Excited for all the good things to come! @MoffittNews @SocSurgOnc
10
2
88
Today is the 20th Anniversary of #MilesForMoffitt. What a unifying and inspiring event that continues to grow!Thanks to all who made it out. ☀️ 🌴 🌴 ☀️ #CancerResearch #CancerAwareness #cancercure #Ahpba @MoffittNews @MHepatobiliary
0
3
8
If you haven’t registered for #MilesForMoffitt don’t worry it’s not until tomorrow AM! You don’t have to be a GI track star to register: https://t.co/lW4AO97wFc No APPs were hurt in the making of this photo. @MoffittNews @MHepatobiliary #cancercure #ahpba
1
3
5
Today is World Pancreatic Cancer Day. We @MoffittNews honor the fighters, the survivors, and the dream of a world free from pancreatic cancer. #pancan #PancreaticCancer #ahpba
0
5
13
Increased surgeon physiological stress during the first 5 minutes of surgery was associated with reduced odds of major surgical complications. Optimizing surgeon stress may provide an opportunity to improve surgical performance and patient outcomes. 🔗 https://t.co/S9MmI1IhrZ
2
23
97
Honored to announce that I’ll be participating in an incredible program with @SocSurgOnc over the upcoming year! Very grateful to be paired with a senior surgeon to mentor me in clinical trials, PSM, and success as a surgical oncologist. @MoffittNews #SSO2026
4
4
27
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%
2
91
259
Registration is officially open for ACT 2026! Join us in Fort Lauderdale, FL as we celebrate the 20th Anniversary of this meeting. Secure your spot: https://t.co/R7QgLv3ZEm
0
7
16
Today ends Appendix Cancer Awareness Month. As a surgical oncologist @MoffittNews, I treat rare cancers like appendix cancer and Pseudomyxoma Peritonei (PMP). Specialized centers and treatments like cytoreductive surgery with HIPEC lead to the best outcomes. @acpmpresearch
1
11
38
There's still time to secure your spot for this week's webinar! Join us to explore treatment strategies for colorectal and appendiceal cancers—including systemic therapy, cytoreductive surgery, and HIPEC. Register before it's too late: https://t.co/9o3ZP2nyw4
0
2
8
Very excited to be included in #FollowFriday and love helping my patients @MoffittNews !
#FollowFriday Meet Dr. Michael Wach, a surgical oncologist in gastrointestinal oncology @MoffittNews. Dr. Wach specializes in treating gastrointestinal cancers that spread to the peritoneum, using cytoreductive surgery and heated intraperitoneal chemotherapy. His research focuses
0
0
24
The X-less Sean Dineen is an expert leader of the Peritoneal Surface Malignancy program at @MoffittNews He and @MikeWach_MD take outstanding care of patients with their multidisciplinary team. Honored to work with him for our #CGSO fellows. @SocSurgOnc
Appendix cancer is rare, but cases are rising, especially among younger generations. For years, Tatiana’s symptoms were dismissed as something minor. But a routine hernia surgery revealed the unexpected: appendix cancer that had silently spread. Her message now? Listen to your
3
7
31
Appendix cancer is rare, but cases are rising, especially among younger generations. For years, Tatiana’s symptoms were dismissed as something minor. But a routine hernia surgery revealed the unexpected: appendix cancer that had silently spread. Her message now? Listen to your
1
16
37
“Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most.” Excellent read from @danielleofri on the reality for clinicians as NIH, CDC, FDA recs are put under political controls. https://t.co/V0gSsea8Ov
nytimes.com
Federal public health institutions were revered by the medical community. That’s rapidly changing.
51
136
399
The 5th annual @MHepatobiliary Complex Surgery Course @MoffittNews is underway! A big welcome to the CGSO fellows and guest faculty Dr. Katz, Dr. Warner, and Dr. Vera. #HPB #SurgOnc #academicsurgery
0
3
19
Featured: National Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( #HIPEC ) in #PeritonealMalignancies : A Worldwide Systematic Review and Recommendations of Strength Analysis. https://t.co/zORucOoeFl
@SchultzKurt
@SyedAAhmad5
0
16
33
#AudioVisualAbstract : Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory #Colorectal and #Appendiceal #Carcinomatosis : Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial @mtalhawaheed
https://t.co/0oXrrXUTGB
@SyedAAhmad5
0
7
17
Excited to share our work summarizing the existing guidelines (Chicago Consensus, PSOGI, NCCN, and the brand new Yale PSM group) for current management of patients with Colorectal Peritoneal Metastases! @SocSurgOnc @AnnSurgOncol @colontown @MoffittNews
https://t.co/eF6tZMbWP6
link.springer.com
Annals of Surgical Oncology - Colorectal peritoneal metastases (CRPM) represent a significant treatment challenge for patients with colorectal cancer that significantly impact quality of life and...
0
5
26
The work of 200+ experts in peritoneal surface malignancies: Guidelines for the management of patients with Colorectal Peritoneal Metastases 🩺🩻🧑🏻⚕️ So proud to be a part of this!
#Consensus guideline for the management of #colorectal #cancer with #peritoneal metastases - Schultz - 2025 - Cancer - Wiley Online Library https://t.co/eV5DFB3J2r Much needed multi-D approach. #CancerResearch @AmericanCancer @VUMCDiscoveries
1
2
13
Absolutely ecstatic to match such a talented group of surgeons to @MoffittNews! Looking forward to many hours of CRS/HIPEC with all of you 🔪🔥
We are thrilled to welcome our newest class of fellows in the CGSO match today. Welcome to the @MoffittNews family! @SocSurgOnc
0
4
35